financetom
Business
financetom
/
Business
/
Australia's Treasury Wine drops planned sale of cheaper brands, cuts profit guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia's Treasury Wine drops planned sale of cheaper brands, cuts profit guidance
Feb 12, 2025 6:07 PM

(Reuters) - Penfolds wine producer Treasury Wine Estates ( TSRYF ) pulled the sale of its cheap drinks division after failing to find an attractive offer and cut its prediction for annual profit, sending its shares tumbling.

The division's weak results and outlook soured an otherwise upbeat first-half result for Australia-listed Treasury as exports to China roared back to life after the end to three years of crippling tariffs imposed by Beijing.

Treasury had planned to offload budget labels including Wolf Bass and Lindeman's last year amid a global trend of young drinkers turning away from alcohol. But "the offers received for these brands did not represent compelling value and therefore their retention is the best course", it said on Thursday.

Net profit excluding one-off items jumped 33% to A$239.6 million ($150 million) in the six months to end-December, just short of the average analyst forecast from data aggregator Visible Alpha.

That owed much to the first full reporting period of exports to China since 2020 and the contribution of recently-bought U.S. winery business DAOU.

But pre-tax profit from its "premium brands" unit, which includes its cheaper wine labels, halved, partly "reflecting softness in consumer demand for wine at lower price points".

Citing reduced expectations for the unit, the company now expects pre-tax profit of about A$780 million for the financial year ending in June. That compares with an earlier estimate of A$780 million to A$810 million.

Treasury shares lost 4% by midsession, having fallen as much as 8% at one point as analysts downgraded their forecasts in line with the new guidance. The overall market was flat.

"With the company deciding not to sell its commercial portfolio, (the premium brands business) might be a drag on group earnings for some time," Citi said in a note.

UBS said the guidance downgrade was "disappointing but somewhat reflected in share price". The stock is down 4% compared to a year ago while the broader market has gained 12%.

Treasury declared an interim dividend of 20 Australian cents per share, compared with 17 Australian cents last year.

($1 = 1.5929 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: RadNet Shares Rise After Q2 Results Beat Estimates
Update: RadNet Shares Rise After Q2 Results Beat Estimates
Aug 11, 2025
10:32 AM EDT, 08/11/2025 (MT Newswires) -- (Updates to include the stock movement in the headline and the first paragraph.) RadNet ( RDNT ) shares rose more than 20% in recent Monday trading after the company posted Q2 results that topped analysts' estimates. The company reported Q2 adjusted earnings Sunday of $0.31 per diluted share, up from $0.16 a year...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Innoviva's Specialty Therapeutics, Royalty Portfolio to Drive Outperformance, Oppenheimer Says
Innoviva's Specialty Therapeutics, Royalty Portfolio to Drive Outperformance, Oppenheimer Says
Aug 11, 2025
10:36 AM EDT, 08/11/2025 (MT Newswires) -- Innoviva's ( INVA ) specialty therapeutics and royalty commercial results are expected to drive outperformance as commercial stories have supported some of the top performing biotech company stocks this year, Oppenheimer said in a note Monday. We believe Innoviva ( INVA ) is an underappreciated commercial story thanks to historical antibiotic commercial challenges,...
Swiss government to meet pharma firms to discuss US tariffs
Swiss government to meet pharma firms to discuss US tariffs
Aug 11, 2025
ZURICH, Aug 11 (Reuters) - The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on its exports, two sources have told Reuters. Economy Minister Guy Parmelin and Health Minister Elizabeth Baume-Schneider will meet with executives from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved